Escaline Facts
Psychedelic;
Description
Escaline (3,5-dimethoxy-4-ethoxyphenethylamine) is a synthetic psychedelic of the phenethylamine class. It activates serotonin receptors in the brain, producing the visual distortions and emotional shifts characteristic of the mescaline family.[1][2]
Subjective effects include geometric visual patterns, color enhancement, emotional warmth, thought connectivity, and time alteration. The experience is broadly mescaline-like — a warm, body-centered psychedelia — but with faster onset and notably less nausea.[3]
Escaline produces no physical dependence, and no lethal dose has been established in any species.safety citation needed The primary risks are psychological — panic, anxiety, and psychosis in predisposed individuals — alongside cardiovascular stimulation that poses danger for those with heart conditions.[4][3]
Dose and durationby route · individual sensitivity varies
Starts in 20 – 45 minLasts 8 – 12 hoursAfter-effects 6 – 24 hours
Body and dependence
- Acute toxicity
- Low
- Chronic toxicity
- Low
- Physical dependence
- None
- Psychological dependence
- Negligible
- Withdrawal
- None recorded
- Compulsive redosing
- Negligible
Tolerance
- Builds
- Rapid
- Fully resets after
- 7 days
- Carries over to
- lsd;
psilocybin; mescaline; dmt; 2c-b
Effectslikely at a common dose
- Perception
- Visual drifting;
Color alteration; Color enhancement; Brightness alteration; Geometry; Visual breathing; +28 possible, including Visual haze / noise, Spatial disorientation, Vestibular distortion - Body
- Stimulation;
Nausea; Pupil dilation; Body high; Body scan awareness; +28 possible, including Muscle tension, Dizziness, Heart rate perception changes - Thinking
- Pattern recognition enhancement;
Novelty enhancement; Conceptual thinking; Aesthetic enhancement; Introspection enhancement; Openness enhancement; +22 possible, including Suggestibility enhancement, Memory suppression, Cognitive impairment - Feeling
- Emotional enhancement;
+8 possible, including Emotional lability, Anxiety, Paranoia - Self
- none likely · 9 possible, including Derealization, Depersonalization
- Time
- Time alteration;
+3 possible, including Temporal disorientation - Transpersonal
- none likely · 1 possible
- Awareness
- none likely · 3 possible
Who shouldn't take it
Combinations61 recorded
Seek help immediately if
Most difficulty is psychological (intense fear, panic, confusion) and passes with calm support — the signs below mean seek emergency help:
- Very high body temperature; hot, dry skin
- Seizures
- Chest pain; fast or irregular heartbeat
- Severe muscle rigidity, tremor, or twitching (possible serotonin syndrome)
- Cold, pale, or blue fingers/toes — severe vasoconstriction (notably NBOMe / DOx)
- Persistent vomiting; unconsciousness; uncontrollable agitation or risk of self-harm
What to do
- Stay calm and reassure — remind them they took a drug and the effect will pass
- Move to a calm, quiet, safe space with low light; reduce noise and sensory input
- Keep them from harm — they may act on fear or confusion; stay with them, don't leave them alone
- Talk them down gently; don't grab or restrain unless they're in danger
- For the medical signs above (overheating, seizure, chest pain, vasoconstriction, unresponsive) call emergency services
- If overheating, cool the body; be ready to give rescue breaths / CPR
The experience is time-limited and usually resolves with calm reassurance in a safe setting — psychological first aid, not medication. Serious physical harm is uncommon for classic psychedelics (LSD, psilocybin) but real for some potent phenethylamines (NBOMe, DOx), where hyperthermia, seizures, and vasoconstriction warrant emergency care.
988 Suicide & Crisis LifelineFireside Project: 62-FIRESIDE
References
- [1]^Blaazer AR, Smid P, Kruse CG (2008) Structure-activity relationships of phenylalkylamines as agonist ligands for 5-HT(2A) receptors — ChemMedChem doi:10.1002/cmdc.200800133
- [2]
- [3]
- [4]^Klaiber A, Schmid Y, Becker AM, Straumann I, Erne L, Jelusic A, Thomann J, Luethi D, Liechti ME (2024) Acute dose-dependent effects of mescaline in a double-blind placebo-controlled study in healthy subjects — Translational Psychiatry doi:10.1038/s41398-024-03116-2